{
  "title": "What this review means",
  "includeSubclaimIllustrations": false,
  "redteamReviewed": true,
  "accessNotice": "Source checking used bounded original primary abstract passages/status records and selected original partial-body passages. No complete-abstract or complete-paper audit, or independent scientific peer review, is claimed. Detailed access counts and limitations appear in the review.",
  "overview": "Laetrile has no demonstrated clinically meaningful benefit in the examined human cancer regimens; oral use can cause serious cyanide poisoning, while newer preclinical delivery studies remain experimental.",
  "implications": "Overall Α follows the preregistered primary SC2 human-regimen clinical-benefit gate. Partial selectivity and experimental activity remain Γ in SC1; they cannot be transferred into the clinical-benefit score. Toxicity avoidance is separately contradicted at Α, and generic care-substitution survival associations remain Β. Route-dependent cyanide harm has its own Ζ model assessment. No finding of toxicity alone determines the benefit grade.",
  "limitations": "67 primary reports with 8 selected partial-body examinations; density, heterogeneous controls and incomplete access set the confidence, not correctness. The grade applies to the exact registered claim; stronger findings for narrower subclaims remain separate. No complete-paper audit or blinded calibration is claimed. This educational review does not establish an individual treatment recommendation."
}